The Institute for Clinical and Economic Review developed an evidence report, including a systematic review of the literature, a cost-effectiveness analysis, and a potential budget impact assessment, to support a public meeting of the California Technology Assessment Forum (CTAF) on October 29, 2015, on sacubitril-valsartan combination therapy (Entresto, Novartis AG) for heart failure (HF).1
Ollendorf DA, Sandhu AT, Pearson SD. Sacubitril-Valsartan for the Treatment of Heart Failure: Effectiveness and Value. JAMA Intern Med. 2016;176(2):249–250. doi:10.1001/jamainternmed.2015.7661
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.